AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 245: R408-R420, 1983;
0363-6119/83 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Powley, T. L.
Right arrow Articles by Laughton, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Powley, T. L.
Right arrow Articles by Laughton, W. B.

AJP - Regulatory, Integrative and Comparative Physiology, Vol 245, Issue 3 408-R420, Copyright © 1983 by American Physiological Society


ARTICLES

Effects of guanethidine sympathectomy on ventromedial hypothalamic obesity

T. L. Powley, M. C. Walgren and W. B. Laughton

Since ventromedial hypothalamic (VMH) lesions apparently produce chronic increases in parasympathetic activity and decreases in sympathetic responses, two experiments were performed to determine whether decreases in sympathetic tone alone are sufficient either to produce elements of the VMH syndrome or to potentiate the expression of the syndrome in animals with lesions. In experiment 1, rats that had been injected with guanethidine sulfate for 5 wk (40 mg X kg-1 X day-1) to produce a permanent sympathectomy (SympX) were maintained on a high-fat diet and subsequently subjected to VMH lesions. In experiment 2, adrenal-demedullated animals were treated with guanethidine for 6 wk and then subsequently underwent VMH lesions. SympX in the studies (81 and 85% depletion of superior cervical ganglia neurons, respectively) did duplicate the effects of VMH lesions on salivary gland weights. In neither experiment, however, did SympX alone or in combination with demedullation mimic the effects of VMH lesions on food intake, body weight, or body fat. Determinations of free fatty acids (FFAs) in the experiments confirmed that VMH lesions elevate basal FFA levels, but they also indicated that effective VMH lesions need not impair the FFA mobilization to 2-deoxyglucose challenges as some basomedial hypothalamic lesions do. In addition, experiment 2, which employed a prolonged period of high-fat feeding, revealed that SympX plus adrenal demedullation could potentiate (a 13% increase) the effects of VMH lesions on body weight. The results taken together do not support the conclusion that a preponderance of the VMH syndrome can be accounted for by the type of reduction in sympathetic tone produced by guanethidine.


This article has been cited by other articles:


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
R. L. Dobbins, L. S. Szczepaniak, W. Zhang, and J. D. McGarry
Chemical sympathectomy alters regulation of body weight during prolonged ICV leptin infusion
Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E778 - E787.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online